Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04533347 | Tafenoquine in Patients With Mild to Moderate COVID-19 | PHASE2 | COMPLETED | 86 | — | — | Feb 19, 2021 | Jun 30, 2022 | Jan 7, 2025 | 10 | United States |
Clinical recovery from COVID-19 symptoms was defined as: temperature \< or equal to 37.7 degrees Celsius (surface by infra-red or oral), respiratory rate \< or equal to 24/minute on room air, shortness of breath is absent on a patient-report scale, and cough is mild or absent on a patient-reported scale.
| Arm | Type | Description |
|---|---|---|
| Tafenoquine | ACTIVE_COMPARATOR | Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10 |
| Placebo | PLACEBO_COMPARATOR | Placebo two tablets 1x/day on Days 1,2,3 and 10 |
| Name | Type | Description |
|---|---|---|
| Tafenoquine Oral Tablet | DRUG | Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10. |
| Placebo | DRUG | Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10. |
Inclusion Criteria: * Male or female, aged ≥18 years of age; * Laboratory confirmed infection with COVID-19 virus by an FDA-authorized SARS-Cov-2 RT-PCR; * Able and willing to give written informed consent. * Willing to keep an electronic diary from Study Day 1 to Study Day 13 (± 1 day) and Study D...